• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LKB1在肺癌发展中的作用。

Role of LKB1 in lung cancer development.

作者信息

Makowski L, Hayes D N

机构信息

Division of Endocrinology, Department of Medicine, Sarah W Stedman Nutrition and Metabolism Center, Duke University Medical Center, Metabolism, and Nutrition, Durham, NC, USA.

出版信息

Br J Cancer. 2008 Sep 2;99(5):683-8. doi: 10.1038/sj.bjc.6604515. Epub 2008 Aug 19.

DOI:10.1038/sj.bjc.6604515
PMID:18728656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2528145/
Abstract

Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identified as frequently altered in lung cancer. LKB1, a kinase inactivated in 30% of lung cancers, is discussed in this review. Loss of LKB1 regulation often coincident with KRAS activation allows for unchecked growth and the metabolic capacity to accommodate the proliferation.

摘要

三种表型相关的遗传综合征及其病变（LKB1、PTEN和TSC1/2）被确定在肺癌中经常发生改变。LKB1是一种在30%的肺癌中失活的激酶，本文对此进行了讨论。LKB1调节的丧失通常与KRAS激活同时发生，从而导致不受控制的生长以及适应增殖的代谢能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ff8/2528145/7c7d97e5267e/6604515f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ff8/2528145/7c7d97e5267e/6604515f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ff8/2528145/7c7d97e5267e/6604515f1.jpg

相似文献

1
Role of LKB1 in lung cancer development.LKB1在肺癌发展中的作用。
Br J Cancer. 2008 Sep 2;99(5):683-8. doi: 10.1038/sj.bjc.6604515. Epub 2008 Aug 19.
2
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.在高加索肺癌患者的肿瘤中经常检测到抑癌基因LKB1的突变，而在亚洲肺癌患者中则不然。
Br J Cancer. 2008 Jul 22;99(2):245-52. doi: 10.1038/sj.bjc.6604469. Epub 2008 Jul 1.
3
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.LKB1/KRAS 突变型肺癌构成了非小细胞肺癌的一个遗传亚组，对 MAPK 和 mTOR 信号通路抑制更为敏感。
Br J Cancer. 2009 Jan 27;100(2):370-5. doi: 10.1038/sj.bjc.6604886.
4
LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.LKB1 在肺癌发生中的作用：一种丝氨酸/苏氨酸激酶作为肿瘤抑制因子。
Protein Cell. 2011 Feb;2(2):99-107. doi: 10.1007/s13238-011-1021-6. Epub 2011 Mar 5.
5
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.己糖胺生物合成途径是 KRAS/LKB1 突变型肺癌的一个可靶向的缺陷。
Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30.
6
An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.LKB1-SIK 轴抑制肺肿瘤生长并控制分化。
Cancer Discov. 2019 Nov;9(11):1590-1605. doi: 10.1158/2159-8290.CD-18-1237. Epub 2019 Jul 26.
7
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.磷脂酰肌醇醚脂质类似物在LKB1突变的非小细胞肺癌细胞中诱导AMP活化蛋白激酶依赖性死亡。
Cancer Res. 2008 Jan 15;68(2):580-8. doi: 10.1158/0008-5472.CAN-07-3091.
8
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.LKB1基因在除黑斑息肉综合征之外的人类癌症中的作用。
Oncogene. 2007 Dec 13;26(57):7825-32. doi: 10.1038/sj.onc.1210594. Epub 2007 Jun 18.
9
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.中国肺腺癌中 LKB1、EGFR 和 KRAS 基因突变谱。
J Thorac Oncol. 2010 Aug;5(8):1130-5. doi: 10.1097/JTO.0b013e3181e05016.
10
The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.致癌性 Ras 的水平决定了 Lkb1 突变组织在体内的恶性转化。
Commun Biol. 2021 Jan 29;4(1):142. doi: 10.1038/s42003-021-01663-8.

引用本文的文献

1
DeepLRHE: A Deep Convolutional Neural Network Framework to Evaluate the Risk of Lung Cancer Recurrence and Metastasis From Histopathology Images.DeepLRHE：一种用于从组织病理学图像评估肺癌复发和转移风险的深度卷积神经网络框架。
Front Genet. 2020 Aug 25;11:768. doi: 10.3389/fgene.2020.00768. eCollection 2020.
2
Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.基于肺癌发生过程中分子生物学的肺腺癌预防及药物研发原理
Onco Targets Ther. 2020 Apr 14;13:3085-3091. doi: 10.2147/OTT.S248436. eCollection 2020.
3
Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.

本文引用的文献

1
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.人类肺癌细胞系中频繁出现的BRG1/SMARCA4失活突变。
Hum Mutat. 2008 May;29(5):617-22. doi: 10.1002/humu.20730.
2
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.一项针对晚期恶性肿瘤患者的I期试验，该试验使用新型雷帕霉素哺乳动物靶点抑制剂地福罗利司（AP23573；MK-8669），每2周静脉注射5天，每日一次。
J Clin Oncol. 2008 Jan 20;26(3):361-7. doi: 10.1200/JCO.2007.12.0345.
3
mTOR: the mammalian target of replication.
基于深度学习的非小细胞肺癌组织病理学图像分类和突变预测。
Nat Med. 2018 Oct;24(10):1559-1567. doi: 10.1038/s41591-018-0177-5. Epub 2018 Sep 17.
4
Fenofibrate prevents skeletal muscle loss in mice with lung cancer.非诺贝特可预防肺癌小鼠的骨骼肌丢失。
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752. doi: 10.1073/pnas.1714703115. Epub 2018 Jan 8.
5
Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.使用二甲双胍靶向代谢和AMP激活的蛋白激酶以使非小细胞肺癌（NSCLC）对细胞毒性疗法敏感：转化生物学及当前临床试验的理论依据
Oncotarget. 2017 Apr 27;8(34):57733-57754. doi: 10.18632/oncotarget.17496. eCollection 2017 Aug 22.
6
Structure of the 14-3-3ζ-LKB1 fusion protein provides insight into a novel ligand-binding mode of 14-3-3.14-3-3ζ-LKB1融合蛋白的结构为深入了解14-3-3的新型配体结合模式提供了线索。
Acta Crystallogr F Struct Biol Commun. 2015 Sep;71(Pt 9):1114-9. doi: 10.1107/S2053230X15012595. Epub 2015 Aug 25.
7
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.LKB1和KRAS改变与脑转移风险：非小细胞肺癌中通过突变分析、拷贝数和基因表达进行的综合特征分析
Lung Cancer. 2014 Nov;86(2):255-61. doi: 10.1016/j.lungcan.2014.08.013. Epub 2014 Aug 30.
8
The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.MZF1/c-MYC轴介导由野生型lkb1缺失引起的肺腺癌进展。
Oncogene. 2015 Mar 26;34(13):1641-9. doi: 10.1038/onc.2014.118. Epub 2014 May 5.
9
Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK.卵泡抑素通过E-钙黏蛋白、LKB1和AMPK控制肺泡增大和上皮细胞存活。
Cell Rep. 2014 Apr 24;7(2):412-423. doi: 10.1016/j.celrep.2014.03.025. Epub 2014 Apr 13.
10
Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.细胞核内的PRAS40将Akt/mTORC1信号轴与RPL11-HDM2-p53核仁应激反应途径联系起来。
Oncogene. 2015 Mar 19;34(12):1487-98. doi: 10.1038/onc.2014.91. Epub 2014 Apr 7.
mTOR：哺乳动物雷帕霉素靶蛋白
J Clin Oncol. 2008 Jan 20;26(3):348-9. doi: 10.1200/JCO.2007.14.3164.
4
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.西罗莫司用于治疗结节性硬化症或淋巴管平滑肌瘤病中的肾血管平滑肌脂肪瘤。
N Engl J Med. 2008 Jan 10;358(2):140-51. doi: 10.1056/NEJMoa063564.
5
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.通过联合抑制MEK和雷帕霉素靶蛋白来靶向人类非小细胞肺癌中的蛋白质翻译
Cancer Res. 2007 Dec 1;67(23):11300-8. doi: 10.1158/0008-5472.CAN-07-0702.
6
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.西罗莫司联合放疗和顺铂治疗非小细胞肺癌的I期试验
J Thorac Oncol. 2007 Aug;2(8):751-7. doi: 10.1097/JTO.0b013e3180cc2587.
7
LKB1 gene mutations in Japanese lung cancer patients.日本肺癌患者中的LKB1基因突变
Cancer Sci. 2007 Nov;98(11):1747-51. doi: 10.1111/j.1349-7006.2007.00585.x. Epub 2007 Aug 16.
8
LKB1 modulates lung cancer differentiation and metastasis.LKB1调节肺癌的分化和转移。
Nature. 2007 Aug 16;448(7155):807-10. doi: 10.1038/nature06030. Epub 2007 Aug 5.
9
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.LKB1基因在除黑斑息肉综合征之外的人类癌症中的作用。
Oncogene. 2007 Dec 13;26(57):7825-32. doi: 10.1038/sj.onc.1210594. Epub 2007 Jun 18.
10
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.依维莫司与吉非替尼用于晚期非小细胞肺癌患者的1期试验。
Cancer. 2007 Aug 1;110(3):599-605. doi: 10.1002/cncr.22816.